<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=319805651697215&amp;ev=PageView&amp;noscript=1">

Cryoport Begins Delivering Novel Cryogenically Preserved Knee OA Treatment to Orthopedists

October 14, 2014

Lake Forest, CA (October 14, 2014) - Cryoport, Inc. (OTC:CYRX) announced today the first phase of deploying its “Regenerative Medicine Point-of-Care Repository Solution” for Liventa Bioscience’s introduction of Liventa’s AmnioClear® LCT therapy to orthopedic clinics in the US. More than 70 orthopedic clinics have expressed interest in the therapy. Of these clinics, approximately 20 have entered into a registry/ clinical study with Liventa.  

Read More


Tags: Dry Shipper, Frozen Shipping, Cold Chain Logistics, cold shipping, Liventa, Regenerative Medicine Point-of-Care Repository Sol, AmnioClear®

Liventa Bioscience and Cryoport form Alliance to deliver cell-based biologics to Point-of-Service Orthopedic Care

February 5, 2014

Philadelphia/Lake Forest - February 5, 2014 - Liventa Bioscience (formerly AFcell Medical) and Cryoport, Inc. (OTC:CYRX)  today  announced a major strategic alliance aimed at serving the many points of orthopedic care delivery with Liventa’s cell-based, advanced biologics tissue forms. The exclusive agreement combines Cryoport’s proprietary, purpose-built cold chain logistics solutions for cell-based and advanced biologic tissue forms with Liventa Bioscience’s distribution capability to “point-of-use” US-based orthopedic care providers.

Read More


Tags: Dry Shipper, Frozen Shipping, Clinical Trials Logistics, Cold Chain Logistics, cold shipping, Liventa